Publications by authors named "I M Tkachenko"
Here, we report on the synthesis and biological evaluation of a novel peptide-drug conjugate, P6-SN38, which consists of the EGFR-specific short cyclic peptide, P6, and the Topo I inhibitor SN38, which is a bioactive metabolite of the anticancer drug irinotecan. SN38 is attached to the peptide at position 20 of the E ring's tertiary hydroxyl group via a mono-succinate linker. The developed peptide-drug conjugate (PDC) exhibited sub-micromolar anticancer activity on EGFR-positive (EGFR+) cell lines but no effect on EGFR-negative (EGFR-) cells.
View Article and Find Full Text PDFArticle Synopsis
- * In vitro tests show that doxorubizen has a significantly stronger effect on reducing cell growth, inducing apoptosis, and inhibiting migration in ATC cells than doxorubicin and lenvatinib alone.
- * The findings indicate that doxorubizen not only works effectively on its own but also enhances the effects of lenvatinib, suggesting potential for future clinical trials in ATC patients.
In this paper, we give an overview of novel main-chain azobenzene-based fluorinated poly(arylene ether)s with different content of azo groups, aiming at providing a better understanding of the link between a number of N═N bonds and the macroscopic response of the material. We discuss chemical synthesis and molecular structure and report on a comprehensive analysis of the polymer properties, thermal behavior, and mechanical strength. We show that a higher content of azobenzene moieties reduces the mechanical strength of the polymer materials.
View Article and Find Full Text PDFObjective: Aim: To study the spectrum, frequency of isolation and level of colonization of dental biofilm with microorganisms in generalized periodontitis against the background of different body reactivity.
Patients And Methods: Materials and Methods: 216 people with the diagnosis of generalized periodontitis. Depending on the state of reactivity of the organism, the patients were divided into 3 groups: with normo-, hyper- and with hyporeaction.
Objective: Aim: The aim of this study was to determine the effect of application of drug with circadian activity (pioglitazone) for treatment of patients with periodontist.
Patients And Methods: Materials and Methods: Group I - 18 individuals with healthy periodontium. Group II - 12 participants with stage II, grade B periodontitis treated with a standard treatment protocol.